SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong

Business Wire India Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that based on related clinical trials and studies of vaccination for local children and adolescents, the Health Bureau of…

Altamira Therapeutics Completes Interim Sample Size Analysis of COVAMID Trial with Bentrio in Acute COVID-19

HAMILTON, BERMUDA , Aug. 01, 2022 (GLOBE NEWSWIRE) — Enrollment to be continued to 160 subjects, adding 24 to ensure adequate statistical power Top-line data read-out from trial expected in early Q4-22 COVAMID trial essential for potential label expansion into…

PERSISTENT LOSS OF SMELL DUE TO COVID-19 CLOSELY CONNECTED TO LONG-LASTING COGNITIVE PROBLEMS

FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2022 Also, ICU Stay May Double Risk of Dementia in Older Adults  SAN DIEGO, July 31, 2022 /PRNewswire/ — New insights into factors that may predict, increase or protect against the impact of COVID-19 and…

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design

NEW YORK and MAINZ, Germany, July 27, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind Phase 2 study to evaluate the safety, tolerability, and immune response…

U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older

Recommendation follows U.S. FDA Emergency Use Authorization for the Novavax COVID-19 Vaccine, Adjuvanted as a two-dose primary series FDA has determined that first vaccine lot has met all release specifications and is acceptable for use under Emergency Use Authorization Novavax…

SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil

Business Wire India Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its COVID-19 vaccine (CoronaVac) has been approved by the Brazilian Health Regulatory Agency (Anvisa) for emergency use in…

U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over

Novavax’ vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. Immunizations with the Novavax COVID-19 Vaccine, Adjuvanted as a primary series will begin upon product release and once a policy recommendation from the CDC is received GAITHERSBURG, Md.,…

Glenmark Pharmaceuticals and SaNOtize Announce Peer Reviewed Publication of Its Phase 3 Clinical Trials on SaNOtize’s Novel Nitric Oxide Nasal Spray for COVID-19 in Lancet Journal

–  The Lancet Regional Health Southeast Asia publishes the successful phase 3 clinical trial results of Nitric Oxide Nasal Spray. –  Phase 3 trial of Nitric Oxide Nasal Spray administered to adult COVID-19 patients in India met the key endpoints…

U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine

Agreement will provide the first protein-based vaccine option in the U.S., pending FDA Emergency Use Authorization and CDC recommendation GAITHERSBURG, Md., July 11, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for…

Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17

Nuvaxovid™ COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 in Europe GAITHERSBURG, Md., July 5, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases,…